Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1998 1
2002 2
2003 2
2004 7
2005 15
2006 25
2007 18
2008 20
2009 20
2010 28
2011 26
2012 29
2013 37
2014 29
2015 31
2016 37
2017 24
2018 23
2019 20
2020 27
2021 25
2022 18
2023 19
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

422 results

Results by year

Filters applied: . Clear all
Page 1
Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis.
Cortese S, Adamo N, Del Giovane C, Mohr-Jensen C, Hayes AJ, Carucci S, Atkinson LZ, Tessari L, Banaschewski T, Coghill D, Hollis C, Simonoff E, Zuddas A, Barbui C, Purgato M, Steinhausen HC, Shokraneh F, Xia J, Cipriani A. Cortese S, et al. Lancet Psychiatry. 2018 Sep;5(9):727-738. doi: 10.1016/S2215-0366(18)30269-4. Epub 2018 Aug 7. Lancet Psychiatry. 2018. PMID: 30097390 Free PMC article.
BACKGROUND: The benefits and safety of medications for attention-deficit hyperactivity disorder (ADHD) remain controversial, and guidelines are inconsistent on which medications are preferred across different age groups. ...In head-to-head comparisons, …
BACKGROUND: The benefits and safety of medications for attention-deficit hyperactivity disorder (ADHD) remain co …
Psychopharmacology of Attention-Deficit Hyperactivity Disorder: Effects and Side Effects.
Golmirzaei J, Mahboobi H, Yazdanparast M, Mushtaq G, Kamal MA, Hamzei E. Golmirzaei J, et al. Curr Pharm Des. 2016;22(5):590-4. doi: 10.2174/1381612822666151124235816. Curr Pharm Des. 2016. PMID: 26601963 Review.
Attention-deficit hyperactivity disorder (ADHD) is a common psychiatric disorder in children which manifests with hyperactivity, impulsivity, and/or inattention. ...Their mechanism of action is the release of dopamine and norepinep …
Attention-deficit hyperactivity disorder (ADHD) is a common psychiatric disorder in children which …
Current Pharmacological Treatments for ADHD.
Groom MJ, Cortese S. Groom MJ, et al. Curr Top Behav Neurosci. 2022;57:19-50. doi: 10.1007/7854_2022_330. Curr Top Behav Neurosci. 2022. PMID: 35507282 Review.
Attention-Deficit Hyperactivity Disorder (ADHD) is a prevalent neurodevelopmental condition associated with impaired function and increased risk of poor outcomes in children, young people and adults with the condition. Currently approved pharmac …
Attention-Deficit Hyperactivity Disorder (ADHD) is a prevalent neurodevelopmental condition associated with impa …
A review of the pathophysiology, etiology, and treatment of attention-deficit hyperactivity disorder (ADHD).
Sharma A, Couture J. Sharma A, et al. Ann Pharmacother. 2014 Feb;48(2):209-25. doi: 10.1177/1060028013510699. Epub 2013 Nov 1. Ann Pharmacother. 2014. PMID: 24259638 Review.
OBJECTIVE: To review the pathophysiology, etiology, and treatment of attention-deficit hyperactivity disorder (ADHD). DATA SOURCES AND DATA EXTRACTION: A literature search was conducted in PubMed and EMBASE using the terms attention deficit …
OBJECTIVE: To review the pathophysiology, etiology, and treatment of attention-deficit hyperactivity disorder (A …
Evidence-based pharmacological treatment options for ADHD in children and adolescents.
Mechler K, Banaschewski T, Hohmann S, Häge A. Mechler K, et al. Pharmacol Ther. 2022 Feb;230:107940. doi: 10.1016/j.pharmthera.2021.107940. Epub 2021 Jun 23. Pharmacol Ther. 2022. PMID: 34174276 Free article. Review.
Attention-deficit hyperactivity disorder (ADHD) is a neurodevelopmental disorder characterized by inattention, hyperactivity, and impulsivity, causing functional impairment. ...Current clinical guidelines recommend an individualized multi …
Attention-deficit hyperactivity disorder (ADHD) is a neurodevelopmental disorder characterized by inatten …
Diagnosis and management of ADHD in children.
Felt BT, Biermann B, Christner JG, Kochhar P, Harrison RV. Felt BT, et al. Am Fam Physician. 2014 Oct 1;90(7):456-64. Am Fam Physician. 2014. PMID: 25369623 Free article.
Attention-deficit/hyperactivity disorder (ADHD) is the most common behavioral disorder in children, and the prevalence is increasing. ...Medications are recommended as first-line therapy for older children. Psychostimulants, such a …
Attention-deficit/hyperactivity disorder (ADHD) is the most common behavioral disorder in children …
The Effects of Drugs used for the Treatment of Attention Deficit Hyperactivity Disorder (ADHD) on Pregnancy Outcome and Breast-feeding: A Critical Review.
Ornoy A, Koren G. Ornoy A, et al. Curr Neuropharmacol. 2021;19(11):1794-1804. doi: 10.2174/1570159X18666201127164000. Curr Neuropharmacol. 2021. PMID: 33245274 Free PMC article. Review.
Attention deficit/hyperactivity disorder (ADHD) is a neurobehavioral condition found in 5-10% of school-age children and in 2-5% of adults. Stimulants affecting the dopaminergic, noradrenergic and/or serotonergic systems are commonly used …
Attention deficit/hyperactivity disorder (ADHD) is a neurobehavioral condition found in 5-10% of school-age c …
Pharmacologic treatment of attention deficit hyperactivity disorder in adults: A systematic review and network meta-analysis.
Elliott J, Johnston A, Husereau D, Kelly SE, Eagles C, Charach A, Hsieh SC, Bai Z, Hossain A, Skidmore B, Tsakonas E, Chojecki D, Mamdani M, Wells GA. Elliott J, et al. PLoS One. 2020 Oct 21;15(10):e0240584. doi: 10.1371/journal.pone.0240584. eCollection 2020. PLoS One. 2020. PMID: 33085721 Free PMC article.
BACKGROUND: Attention deficit hyperactivity disorder (ADHD) affects approximately 3% of adults globally. ...Notably, only 5 RCTs were deemed at overall low risk of bias. Included pharmacotherapies were methylphenidate, atomoxetine, dexamf …
BACKGROUND: Attention deficit hyperactivity disorder (ADHD) affects approximately 3% of adults globally. ...Nota …
The pharmacological and non-pharmacological treatment of attention deficit hyperactivity disorder in children and adolescents: A systematic review with network meta-analyses of randomised trials.
Catalá-López F, Hutton B, Núñez-Beltrán A, Page MJ, Ridao M, Macías Saint-Gerons D, Catalá MA, Tabarés-Seisdedos R, Moher D. Catalá-López F, et al. PLoS One. 2017 Jul 12;12(7):e0180355. doi: 10.1371/journal.pone.0180355. eCollection 2017. PLoS One. 2017. PMID: 28700715 Free PMC article.
BACKGROUND: Attention deficit hyperactivity disorder (ADHD) is one of the most commonly diagnosed psychiatric disorders in childhood. ...Stimulants and non-stimulants seemed well tolerated. Among medications, methylphenidate, amphe …
BACKGROUND: Attention deficit hyperactivity disorder (ADHD) is one of the most commonly diagnosed psychiatric di …
422 results